A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Mark Herzberg is a Professor of Clinical Haematology involved in clinical trials for patients with blood cancers, particularly lymphoma, leukaemia, and myeloma, in Australia and New Zealand.
Hodgkin lymphoma is a common cancer with varied symptoms, and treatment typically involves chemotherapy and sometimes radiation therapy.
Approximately 800 Australian patients are diagnosed with advanced stage Hodgkin lymphoma each year, with staging determined through imaging and blood tests.
Advanced stage Hodgkin lymphoma is treated with outpatient combination chemotherapy using two major regimens (ABVD and escalated BEACOPP) worldwide, with a global clinical trial involving nine cooperative groups in nine countries and 1500 patients.
The ALLG contributed 115 patients across 16 sites in Australia and New Zealand to a groundbreaking clinical trial.
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen incorporating a new drug, Brentuximab Vedotin.
Patients experienced fewer side effects, such as anaemia, low platelet counts, peripheral neuropathy, and gonadal toxicity, while preserving fertility, with the modified BrECADD regimen in the treatment of advanced stage Hodgkin lymphoma.
Most patients with advanced stage Hodgkin lymphoma remained disease-free after three years of treatment, with a significant reduction in toxicity and shorter duration of treatment, allowing them to resume normal life and work sooner.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Australian Healthcare Week 2019: Pitch Fest Finalist Lumin
Startup company Lumin was a Pitch Fest Finalist at last week’s Australian Healthcare Week Expo in Sydney. The Lumin platform is used in aged care where loneliness and isolation can be a trigger for stroke and dementia. Lumin helps the connection to care providers, family members and duress monitoring services in a device that has been designed for those with dementia, vision impairment or find complex devices difficult to use.
Managing Director and Co-Founder Paul Wilson spoke at the Mepacs booth with Anne Dao from Australian Health Journal about the market they target and the design of the user experience, including the remote servicing and monitoring. The integration allows the monitoring team in the call centre see and hear the personal raising the alarm. Mepacs is a provider of personal duress alarms and have teamed up with Lumin.
-
Empowered nurses leading digital health enablement
Nurses have a pivotal role to play in the widespread implementation and adoption of digital health technologies throughout the healthcare sector for the primary purpose of improving safety and quality of patient care.
Australian Health Journal talked to two of Australian top leaders in nursing and in digital health on how the role of nursing is pivotal to the success of digital health in the Australian health system.
-
Maximising benefits, minimising harms in population health screening
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
